Physician profile
Anna Borneman
NPI 1770101958
$3,549.45
in general payments reported to CMS, 2019-2025
24 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.69 · 2022: $126 · 2023: $992 · 2024: $1,273 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.19 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $377.55 | 2023-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $355.05 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $345.72 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $278.28 | 2023-2024 | Otezla, Prolia, Evenity |
| Astellas Pharma US INC | $226.99 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $141.72 | 2023-2025 | Rexulti |
| Pfizer INC. | $133.43 | 2023-2025 | |
| Boston Scientific Corporation | $131.42 | 2023 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.68 | 2023-2025 | Xifaxan, Trulance |
| Antares Pharma, INC. | $109.38 | 2022-2025 | Xyosted |
| Pharmacosmos Therapeutics INC. | $101.01 | 2023 | Monoferric |
| Esperion Therapeutics, INC. | $99.49 | 2024-2025 | Nexletol |
| Glaxosmithkline, LLC. | $88.25 | 2022 | |
| Exact Sciences Corporation | $64.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.10 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.42 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $40.08 | 2022-2023 | Quviviq |
| Verity Pharmaceuticals INC. | $38.75 | 2024 | Tlando |
| Teva Pharmaceuticals USA, INC. | $24.29 | 2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $22.93 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $20.01 | 2024 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $19.81 | 2023 | Livalo |
| Biogen, INC. | $16.95 | 2025 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Borneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.